Gilead and Japan Tobacco Sign Licensing Agreement

Gilead Sciences today announced that the company has entered into a licensing agreement with Japan Tobacco, under which JT has granted to Gilead exclusive rights to develop and commercialize a novel HIV integrase inhibitor (JTK-303) in all countries of the world, excluding Japan, where JT will retain rights. Under the terms of the agreement, Gilead will pay to JT an upfront payment of $15 million and additional cash payments of up to $90 million upon the achievement of certain milestones.

Yahoo News (http://biz.yahoo.com/bw/050322/216013_1.html)